New diagnostic criteria for urinary cytology
In recent years, urinary cytology has assumed an increasingly central role in the diagnosis and monitoring of urothelial malignancies, particularly high-grade carcinomas. In this context, the upgrade to version 2.0 of The Paris System (TPS) is a key step in improving diagnostic accuracy, reproducibility of reports, and communication between laboratoryists and clinicians.
What is The Paris System 2.0
The second edition of The Paris System 2.0 was created with the aim of refining the criteria already introduced in the first version, published in 2016. The system continues to focus primarily on the identification of high-grade urothelial neoplasms (HGUCs), which are considered more clinically relevant than low-grade lesions.
The update introduces clarifications, changes in morphologic criteria, and a better definition of diagnostic categories, reducing interpretative ambiguities.
The update introduces clarifications, changes in morphologic criteria, and a better definition of diagnostic categories, reducing interpretative ambiguities.
The main diagnostic categories
TPS 2.0 maintains a standardized categorical structure, including:
- Non-diagnostic/insufficient specimen
- Negative for high-grade urothelial carcinoma
- Urothelial atypia (AUC)
- Suspicious for high-grade urothelial carcinoma
- High-grade urothelial carcinoma (HGUC)
- Other neoplasms (including variants and non-urothelial tumors)
One of the major changes concerns greater precision in defining the AUC category, which historically has been a "gray area" in reporting.
- Non-diagnostic/insufficient specimen
- Negative for high-grade urothelial carcinoma
- Urothelial atypia (AUC)
- Suspicious for high-grade urothelial carcinoma
- High-grade urothelial carcinoma (HGUC)
- Other neoplasms (including variants and non-urothelial tumors)
One of the major changes concerns greater precision in defining the AUC category, which historically has been a "gray area" in reporting.
New morphological criteria: what changes
The second edition introduces significant updates in cytology criteria, including:
1.Better definition of nucleus/cytoplasm ratio
The N/C ratio remains a key parameter, but TPS 2.0 provides more detailed guidance on how to assess it consistently, reducing inter-observer variability.
2.Greater emphasis on nuclear features
Items such as hyperchromasia, nuclear membrane irregularities, and coarse chromatin are better standardized, with more precise examples and descriptions.
3.Revision of quantitative criteria
Cut-offs regarding the minimum number of atypical cells needed for some diagnostic categories have been updated, improving sensitivity without compromising specificity.
1.Better definition of nucleus/cytoplasm ratio
The N/C ratio remains a key parameter, but TPS 2.0 provides more detailed guidance on how to assess it consistently, reducing inter-observer variability.
2.Greater emphasis on nuclear features
Items such as hyperchromasia, nuclear membrane irregularities, and coarse chromatin are better standardized, with more precise examples and descriptions.
3.Revision of quantitative criteria
Cut-offs regarding the minimum number of atypical cells needed for some diagnostic categories have been updated, improving sensitivity without compromising specificity.
Clinical implications
The adoption of The Paris System 2.0 has important spin-offs in clinical practice:
- Increased diagnostic accuracy: better identification of high-grade carcinomas
- Reduced false positives: due to more stringent criteria
- Clearer communication with the clinician: standardized and interpretable reports
- Support for treatment decisions: especially in the follow-up of patients with a history of bladder cancer
- Increased diagnostic accuracy: better identification of high-grade carcinomas
- Reduced false positives: due to more stringent criteria
- Clearer communication with the clinician: standardized and interpretable reports
- Support for treatment decisions: especially in the follow-up of patients with a history of bladder cancer
Importance of prevention and monitoring
Recognizing an individual at risk allows effective preventive measures to be implemented, such as smoking cessation, reducing exposure to toxic substances, and regular monitoring through clinical examinations. In the most relevant cases, monitoring may include customized surveillance programs.
The role of Urine24
In a context where standardization is crucial, entities such as Urine24 aim to integrate the new TPS 2.0 criteria into daily diagnostic workflows, ensuring:
- Continuous updating of staff
- Strict application of international guidelines
- Quality and uniformity in cytology reporting
- Continuous updating of staff
- Strict application of international guidelines
- Quality and uniformity in cytology reporting
Conclusion
The introduction of The Paris System 2.0 represents a significant evolution in urinary cytology. The new diagnostic criteria improve the accuracy and consistency of reports, contributing to more effective patient management.
For professionals in the field, staying up-to-date with these guidelines is not only a scientific necessity, but a key element in ensuring diagnostic quality and clinical safety.
For professionals in the field, staying up-to-date with these guidelines is not only a scientific necessity, but a key element in ensuring diagnostic quality and clinical safety.
